



Abstract of the Disclosure

A vaccine, effective in inducing the production of antibodies with which to immunize a second subject passively against infection by Gram-negative bacteria and  
5 LPS-mediated pathology, comprises a non-covalent polyvalent complex formed between purified, detoxified LPS derived from *E. coli* and purified outer membrane protein derived from *N. meningitidis*. The same vaccine will also actively immunize a host subject against Gram-  
10 negative bacterial infections and LPS-mediated pathology. Meningococcal infections are included among those Gram-negative bacterial infections protected against by the vaccine.